/ en Fri, 01 Aug 2025 12:26:24 -0500 Thu, 31 Jul 25 15:28:05 -0500 /340b-advocacy-alliance-bulletin/2025-07-31-aha-340b-advocacy-alliance-newsletter <p><strong>HHS announces new 340B Rebate Model Pilot Program</strong></p><p>The Department of Health and Human Services today issued a <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGcARMDjHMaBXRQp0v86AMFhrGU7ioHD1bfWpFPh2bPbpe828FAdPU7ZfdK-7MYIvgKpdr5ZOc%3D&data=05%7C02%7Cdsamuels%40aha.org%7C2c25cc95794b434c647308ddd0706eb7%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638895903528566195%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NPE1OFrofQ1b2qZCIxsBN%2BYXDTt3ZViD4yAV7U6utG0%3D&reserved=0" target="_blank">notice</a> announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug manufacturers to effectuate the 340B ceiling price on select drugs to all 340B covered entities.</p><p>The notice said HHS’ Health Resources and Services Administration’s Office of Pharmacy Affairs, which currently oversees the 340B Drug Pricing Program, is inviting certain drug manufacturers to apply for participation in the pilot program for a minimum of one year. HRSA said the pilot program will be limited to the NDC-11s included on the Centers for Medicare & Medicaid Services’ <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGcARMDjLse-JuOTvKr3cnodllvUn9U26PJ2LeGicYW_44gPEQYngbMHAoaj98vztg0g3nChZo%3D&data=05%7C02%7Cdsamuels%40aha.org%7C2c25cc95794b434c647308ddd0706eb7%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638895903528579007%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=M4pqWqEPHAytM57cXUbEShFC28OS6f%2FYbs6I2noqSWM%3D&reserved=0" target="_blank">Medicare Drug Price Negotiation Selected Drug List</a> regardless of payer.</p><p>HRSA said manufacturers must submit applications to participate in the pilot program by Sept. 15 and approvals will be made by Oct. 15 for a Jan. 1, 2026, effective date.</p><p>In a <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGcARMDjKtaUQYaz2Kbtb3M5z8MTSy1REn_9vpnBJ4HxlbC9MQuRGOTCs7G4y-0Z8QRqrrntVM%3D&data=05%7C02%7Cdsamuels%40aha.org%7C2c25cc95794b434c647308ddd0706eb7%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638895903528591682%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=DvT3uYWBbtNbfeYDsaasVEZfiK%2BNr9erOylgxPDkKgQ%3D&reserved=0" target="_blank">statement shared with the media</a> following release of the notice, AHA Vice President of Advocacy and Grassroots Aimee Kuhlman said, “The AHA looks forward to reviewing HRSA’s 340B rebate guidance in more detail and working with the agency on this issue. However, we are concerned that this guidance authorizes a significant departure from how the 340B program has successfully operated for decades and sets a dangerous precedent for possible harmful expansions in the future. This pilot program is a response to a nonexistent program integrity problem that the drug manufacturers have manufactured in the public discourse.</p><p>“Nevertheless, we appreciate HRSA’s efforts to impose strict guardrails on its limited pilot program. Going forward, it will be essential that HRSA makes certain that the drug companies bear all the costs of implementing these rebate models and that those companies provide discounts expeditiously. Anything else will pose serious financial risks to patients, communities and the hospitals that care for them.”</p><p><strong>The agency is soliciting comments on the structure and application process of the 340B Rebate Model Pilot Program. Those comments are due Aug. 31. AHA 340B members will receive a Regulatory Advisory with more details on the notice. In addition, the AHA will submit comments in advance of the deadline and encourages members to submit their own comments explaining the potential harms of the rebate model and why strengthened guardrails for the pilot program are necessary.</strong></p><p>The rebate issue is the subject of multiple ongoing court cases in which drug companies have sued HHS for denying their requests to impose rebate models rather than the longstanding upfront discount model that HHS has allowed since the outset of the program. The AHA has filed several amicus briefs in these cases, and it intends to file another brief in the United States Court of Appeals for the D.C. Circuit next week.</p><p>In addition, the AHA May 9 sent a <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGcARMDjCDO5cRzNvms_5ZuDXgkHq0obmeov9nEkOgpPfCDkcv3e9rRbdUYQln0Q31rNbspBXU%3D&data=05%7C02%7Cdsamuels%40aha.org%7C2c25cc95794b434c647308ddd0706eb7%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638895903528604462%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=w5Lp0yTqieTZ1qHsOa%2B%2FV3IbUZ3O6YrWNW0ulinTHe4%3D&reserved=0" target="_blank">letter to HHS</a> urging the agency to deny drug companies’ requests to approve their “unlawful rebate models,” as they would “come at the expense of America’s most vulnerable patients and communities.”</p><p>If you have questions, please contact Bharath Krishnamurthy, AHA director of health analytics and policy, at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGcARMDjImSA-8QOA_YnCqLuGiptnn1orY7v3ftgOwZUJ5WlcMGM8jsJBnExyTAH9z_5YfyY20%3D&data=05%7C02%7Cdsamuels%40aha.org%7C2c25cc95794b434c647308ddd0706eb7%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638895903528618824%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=77GbLmxxcr9E8aJcFT%2B82GpjQz9q064GqlvqyPCTzWI%3D&reserved=0" target="_blank">bkrishnamurthy@aha.org</a>. </p> Thu, 31 Jul 2025 15:28:05 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-07-29-340b-advocacy-alliance-bulletin-july-29-2025 <p><strong>Register for Aug. 1 AHA Site-neutral Advocacy Alliance Call</strong></p><p>The AHA’s Site-neutral Advocacy Alliance will meet on Friday, Aug. 1, at 1 p.m. ET. This call will feature updates on the site-neutral provisions in the Centers for Medicare & Medicaid Services’ calendar year 2026 outpatient prospective payment system proposed rule. See <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb9kXtf980Li3lMtmTHxP4AWir0m_q9psts9_yniXiqFnwYuyj-ZNB3vACsLdk_2aS3ljxk6s%3D&data=05%7C02%7Cdsamuels%40aha.org%7C8151afaf47534458cca008ddcec83129%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638894081397935808%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=E%2Fxlvltcg%2FSEUxyQa%2FsNIQYH7lN7PkFd%2FbuaNCiYrY4%3D&reserved=0" target="_blank">AHA’s Regulatory Advisory</a> for a detailed summary of the rule.</p><p class="text-align-center"><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb9kXtf9HlESG8SsxlYBrhcG-W05jurPpaAezo9XQOqu9opwtUcLVW-UkKpeO91tCHrz5ulAE%3D&data=05%7C02%7Cdsamuels%40aha.org%7C8151afaf47534458cca008ddcec83129%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638894081397949211%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=iJ1yrgQXJjqewrnTgvZC1y2Ed1XEha1AvgzrN9dmjJI%3D&reserved=0" target="_blank"><strong>Register for the Aug. 1 call.</strong></a></p><p>In the CY 2026 OPPS proposed rule, CMS proposes to use its statutory authority regarding a “method to control for unnecessary increases in the volume of outpatient services” to impose a site-neutral payment reduction for drug administration procedures furnished in grandfathered (excepted) off-campus provider-based departments. The site-neutral payment rate would be set at 40% of the OPPS payment rate. The agency proposes to exempt rural sole community hospitals from this proposed policy. CMS proposes to use the same statutory authority it used in 2019 to impose site-neutral payment reductions for clinic visit services in grandfathered (excepted) off-campus PBDs. As with the clinic visits, CMS proposes to implement this in a non-budget-neutral manner, estimated to save $280 million in 2026 and nearly $11 billion over 10 years. The agency also requests comments on other services to which it should consider applying site-neutral payment reductions using this “unnecessary increases in the volume of services” authority, noting specifically on-campus clinic visits and imaging without contrast services in grandfathered off-campus PBDs.</p><p><strong>Site-neutral Advocacy Resources</strong><br>Visit the AHA’s Site-neutral Payment Proposals <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb9kXtgCU3O2LsniSWRWjuyOV-i2flY_G4p8VSAzFOzD1L5XIt2x9PGEujACGpTrlL_wTQwd8%3D&data=05%7C02%7Cdsamuels%40aha.org%7C8151afaf47534458cca008ddcec83129%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638894081397962144%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jWe4md9ooXa%2F5cj7J3nFjeM0NiVvscojhRI0VA3PAzA%3D&reserved=0" target="_blank">Advocacy Issue page</a> for additional resources to assist in your advocacy efforts.</p><p><strong>Further Questions</strong><br>If you have further questions, please contact Roslyne Schulman, AHA’s director of policy, at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb9kXtgKzlWuRJQUUN1b2w-VadNMHIa6E0VVZ0SGOn5yOxqpwLjkC1T31KOFmM1hfzbm22SD4%3D&data=05%7C02%7Cdsamuels%40aha.org%7C8151afaf47534458cca008ddcec83129%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638894081397974835%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=MoFitHq6c3PtEK7Wyc8y94q382aHO4W%2B0UeLhvyrwbM%3D&reserved=0" target="_blank">rschulman@aha.org</a>, or Jason Kleinman, AHA’s director of federal relations, at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb9kXtfzBr0qSkDPJukXGnt8InSoJ06qNpRSkm-NqpxWhD23jpgy2o6zbRKpPmFDp5WEr1h5A%3D&data=05%7C02%7Cdsamuels%40aha.org%7C8151afaf47534458cca008ddcec83129%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638894081397987481%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=mkwIg65vEhFLJCW%2FWnvplWrt6cM%2Fn%2Fa%2BP8IPnZUADuY%3D&reserved=0" target="_blank">jkleinman@aha.org</a>.</p> Tue, 29 Jul 2025 14:58:10 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-07-28-aha-340b-advocacy-allianace <p><strong>REMINDER: Register for July 29 AHA call on 340B provisions in the OPPS and PFS rules</strong></p><p>The AHA 340B Alliance July 29 at 3 p.m. ET will host a call for AHA members about 340B proposals contained in the hospital outpatient prospective payment system and physician fee schedule proposed rules for calendar year 2026. On the call, AHA staff will provide an overview of the 340B proposals contained in the Centers for Medicare & Medicaid Services regulations, as well as provide other updates related to the 340B Drug Pricing Program.</p><p><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb8bCAoNs-OUIkno4qbWw2RTbXCClcGR7lp1QX-KDq0cAi_uWmNkRM1n_dXAX8531uBhxWrtU%3D&data=05%7C02%7Cdsamuels%40aha.org%7C985aaa52980049e224e208ddce15248e%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638893312412065282%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=ZtFa5W8lTKLBy7DLIWjQCC%2FuhYZTybSnGVqWwScHNRg%3D&reserved=0" target="_blank"><strong>REGISTER</strong></a><strong> by Tuesday, July 29 at noon ET, if you have not already done so. If you have trouble registering, please contact Candice Dailey at </strong><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb8bCAoPCxXcrkwMYkA2PPF4q1ypBFgeRi3Wo87t34k1Al7EeKEKt5xunstK-9_qWfXqcTj4I%3D&data=05%7C02%7Cdsamuels%40aha.org%7C985aaa52980049e224e208ddce15248e%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638893312412078609%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=a0XBFcgkvla3kiUYhaErVL4TSXQ5IJ%2BzvV90HRsgaqw%3D&reserved=0" target="_blank"><strong>cdailey@aha.org</strong></a><strong>.</strong></p><p>For more information on the rules being discussed, read the <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb8bCAoD0KNbqcdXmszEzMEEtZFeA6D0eRP_fKCZFbpbJ9arDa5ReksKmgqHc7Claw2dNeabM%3D&data=05%7C02%7Cdsamuels%40aha.org%7C985aaa52980049e224e208ddce15248e%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638893312412091418%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=3vQej%2BFr7MOseaYkPNwM2UO%2BeafqMbeHgnshY86Lvdc%3D&reserved=0" target="_blank">July 16 AHA Regulatory Advisory</a> on the outpatient prospective payment proposed rule and the <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGb8bCAoDmHgdj1KOXF29irepXNNHdNGtn4rdFIaHQA-Z4UBWNO9MqCB2llY1L9pUu_b3b1ugk%3D&data=05%7C02%7Cdsamuels%40aha.org%7C985aaa52980049e224e208ddce15248e%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638893312412104207%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bMgbMwMhCkRSz33wBbdFSk1B%2BpaqEvvXaItH4XB%2FoM8%3D&reserved=0" target="_blank">July 15 AHA Regulatory Advisory</a> on the physician fee schedule proposed rule.</p> Mon, 28 Jul 2025 09:10:56 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-07-17-340b-advocacy-alliance-bulletin-july-17-2025 <p><strong>AHA releases summaries of OPPS, PFS proposed rules with 340B proposals</strong></p><p>The AHA recently released summaries of the hospital outpatient prospective payment system and physician fee schedule proposed rules for calendar year 2026 that were released this week by the Centers for Medicare & Medicaid Services. Both rules have sections related to the 340B program. See details below and in the referenced Regulatory Advisories. Watch for more information, including an upcoming 340B Advocacy Alliance call to discuss the latest on the 340B Program.</p><p><strong>CY 2026 OPPS Proposed Rule: 340B Proposals</strong></p><p>CMS said it is reconsidering the timeline for which all OPPS hospitals must repay the government for the $7.8 billion in increased payments they received for non-drug services between CYs 2018-2022 as a result of the agency’s budget-neutral policy to cut payments to 340B hospitals that was unanimously struck down by the Supreme Court. In prior rules, the agency had finalized repayments through an annual 0.5% reduction to the OPPS conversion factor starting in CY 2026 until the full $7.8 billion was repaid, which the agency had estimated would take 14 years. The agency now proposes to shorten the timeline so that the $7.8 billion is repaid by CY 2031 through a 2% annual reduction to OPPS conversion factor.</p><p>In a statement shared with the media, AHA said it was “concerned with CMS’ proposal to claw back billions of dollars from hospitals at a far faster rate than originally promised. It is important to remember that this clawback punishes 340B hospitals for the agency’s own mistake in implementing a policy that a unanimous Supreme Court held to be unlawful. Doubling down on that unlawfulness, the proposed recoupment is both illegal and unwise, and it should not be finalized.”</p><p>In a related proposal, CMS also announces a new drug acquisition cost survey beginning in late CY 2025 into early CY 2026 for all hospitals paid under the OPPS for separately payable drugs. The results of the survey would be compiled and used to set payment rates for separately payable drugs in CY 2027 rulemaking.</p><p>AHA also expressed concern about the proposal to pursue a burdensome acquisition cost survey, especially if the agency’s goal is to drastically reduce Medicare payments to hospitals that serve the nation’s most vulnerable communities.</p><p><strong>Read the July 16 </strong><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbuB1sgFygC2xyVqnD54YnjZzPmXBp-4U045z-c4EMC41YRsiB1j3A_xBWDiP0m5cCOqfNnas%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cb0c9f57a28a944b1e85608ddc54cc416%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638883655715400810%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=21T6NxGUhVYQBMYezQaM4TH6IGGGeZ773YwAU1jW1RU%3D&reserved=0" target="_blank"><strong>AHA Regulatory Advisory</strong></a><strong> for more details on these and other proposals.</strong></p><p><strong>CY 2026 PFS Proposed Rule: 340B Proposals</strong></p><p>CMS proposed creating a new claims-based methodology to remove units of drugs purchased under the 340B program for the purposes of calculating Medicare drug inflation rebates. The agency also proposed to create a 340B claims data repository allowing voluntary data submission by 340B providers to potentially use for the same purpose.</p><p>AHA appreciates the recognition of the complexity of identifying Medicare Part D drug units purchased under the 340B drug pricing program. As we review the agency’s proposals in more detail, we caution against any approach that would add unnecessary burden on 340B hospitals or would allow sensitive 340B data to be used outside the scope of the Medicare drug inflation rebate program to diminish the value of the program to 340B hospitals and their patients.</p><p><strong>Read the July 15 </strong><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbuB1sgJFOrLVQH3rsOsY3m5es9tJVnDMOwbaxnTje9H_LPfcbOuLBKNVIeVFVWI1SnYFIbY8%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cb0c9f57a28a944b1e85608ddc54cc416%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638883655715413782%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bo2WEhaIZMEfWtfw6U9cjy7zMUkRWL1W9Sfu%2BdN7awI%3D&reserved=0" target="_blank"><strong>AHA Regulatory Advisory</strong></a><strong> for more details on these and other proposals.</strong></p><p>If you have questions, contact Bharath Krishnamurthy, AHA director of health analytics and policy, at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbuB1sgFFY220k266DFtvxF8nMriyJlOaAulbhsuRuSoOiymXR057g3AMONsyV4mUW6yInCGI%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cb0c9f57a28a944b1e85608ddc54cc416%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638883655715426327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=2cG3%2B%2FwoF3ZrXHqdIX2uzlTTyMJdr66Kqu9DCvBTtaw%3D&reserved=0" target="_blank">bkrishnamurthy@aha.org</a>.</p><hr><p><strong>Rural patients significantly benefit from 340B program, says Nebraska newspaper op-ed</strong></p><p>“Using 340B savings, our hospital has invested in new equipment, technology, services, and professional support to meet the unique healthcare needs of our rural community. Cutting the 340B Program would undermine our ability to make these valuable investments and continue providing high-quality, affordable, and accessible healthcare for our community,” says an <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbuB1sgHznxABZ8T-Pjlkqpsh2wBHkxYAdO8R9O0b509qFhrnaYWG6KbAgdnTZ79h2uD7i1gk%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cb0c9f57a28a944b1e85608ddc54cc416%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638883655715438833%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=1c3hbVpU4L689skx5yUaPSs0aISd5%2BrmaAQXIigFhok%3D&reserved=0" target="_blank">op-ed</a> in the Tecumseh Chieftain authored by Olivia Little, Johnson County Hospital 340B director, and Mary Kent, Johnson County Hospital CEO.</p><p>“As grateful as local rural hospitals are to Nebraska lawmakers and Governor Pillen for their work to protect the 340B Program at the state level, we need the same kind of support from our leaders in Washington,” said Little and Kent, in reference to Nebraska Gov. Jim Pillen’s July 16 signing of the 340B Contract Pharmacy Protection Act. “Protecting this program is critical to prescription drug access for the rural, underserved, and disadvantaged patients and communities the 340B Program was designed to help.”</p> Thu, 17 Jul 2025 13:59:36 -0500 340B Advocacy Alliance Bulletin /2025-06-27-aha-340b-advocacy-alliance-bulletin-june-27-2025 <p><strong>Judge rules against J&J, for HHS and 340B hospitals in rebate model case</strong></p><p>A U.S. District Court for the District of Columbia judge today <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbUcvzuE3T_K40xBPMGKcwXKhBF_eDgXMr6F4CyqLloA8We6SrFZa3Tq7WX4VyPJRMLxgp8j0%3D&data=05%7C02%7Cdsamuels%40aha.org%7C248ab5b421a7413e02bc08ddb5af5468%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638866486843026390%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=L%2FP0D4qH4Ij2MHFUWp4Am%2FICrTN6TGbVySg%2BTlneFQ8%3D&reserved=0" target="_blank">ruled</a> against Johnson and Johnson and sided with the Department of Health and Human Services and hospitals in a lawsuit brought by J&J challenging the government’s authority to reject J&J’s proposed 340B rebate model.</p><p>“In sum, based on the plain and unambiguous language of the 340B statute, and supported by its purpose and history, HRSA has the authority to ‘provide’ for discounts, rebates, or both,” Judge Rudolph Contreras wrote. “This conclusion defeats J&J’s claim that HRSA lacked the authority to require prior approval of J&J’s rebate model.”</p><p>The AHA in a <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbUcvzuNsC2ss0u8UfjxCys-sqUIczRzEYQfCXi9N08B4F2UeKSnDvVHfHz3xKNmyQyYwRCcc%3D&data=05%7C02%7Cdsamuels%40aha.org%7C248ab5b421a7413e02bc08ddb5af5468%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638866486843039188%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=WcxeiJdc3nBbR9xJ1z71F37MEZAQJdRmTsodhTkfl1A%3D&reserved=0" target="_blank">friend-of-the-court brief</a> urged the court to uphold the government’s decision to reject J&J’s proposed 340B rebate model. Others joining the AHA in the filing were the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.</p><p>Earlier this year, a second district judge reached the <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbUcvzuP7xCHrSK6TxECf1s-ELHpJJA7oIv4mukuujlOBVMUN3VWdUA_QTsEv9tA0O9xlSG-s%3D&data=05%7C02%7Cdsamuels%40aha.org%7C248ab5b421a7413e02bc08ddb5af5468%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638866486843053753%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=BJYO7KxuB5Hnz%2FMkEAE7%2BcxUO5HPfI55Bc5dpMnsNnM%3D&reserved=0" target="_blank">same conclusion</a> in cases brought by five other drug companies. </p> Fri, 27 Jun 2025 15:01:52 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-06-16-340b-advocacy-alliance-bulletin-june-13-2025 <p><strong>AHA report: Hospitals are complying with 340B rules, but drug companies are not</strong></p><p>The AHA today released a <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbGNAlcpb6Q2eUdEnaepRxIQQE9iUqXzjdGQR5iBcjmrIKsfUoVCM8wMApq8mPEYDZwTmsobo%3D&data=05%7C02%7Cdsamuels%40aha.org%7C4b7859bbf9444cf6d5f908ddacfd6c05%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638856926657797391%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Yi%2F965jWatafqzXaztpQ3fizLc94iTYhIaGV1JnZ8pA%3D&reserved=0" target="_blank">report</a> showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater oversight by the federal government, but they also significantly outperform drug companies in terms of program compliance.</p><p>The report analyzed publicly available federal audit data and observed trends in findings for both 340B hospitals and drug companies from fiscal years 2018-2022. Duplicate discount and diversion findings in 340B hospital audits have declined significantly, reflecting very high rates of compliance in recent years, according to the report. Meanwhile, of the audits conducted for drug companies during the same period, 60% had at least one adverse finding, and 93% of those with an adverse finding were required to issue repayments to 340B providers.</p><p>“Policymakers should reject the baseless claims made by drug companies of widespread program abuse by 340B hospitals and urge HRSA [Health Resources and Services Administration] to increase their audits of drug companies,” the report notes. “Greater oversight of these drug companies is necessary to ensure the continued success of the 340B program for the millions of vulnerable patients and communities nationwide who rely on it.”</p> Mon, 16 Jun 2025 13:16:35 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-06-13-340b-advocacy-alliance-bulletin-june-13-2025 <p><strong>Digital ad campaign highlights how the 340B program supports patients and communities</strong></p><p>The AHA, along with other national hospital groups, is currently running a digital ad campaign highlighting for policymakers the benefits of the 340B Drug Pricing Program to patients and communities and the danger of drug company-backed unlawful 340B rebate models. The ads, which link to websites with more information about the benefits of 340B, kicked off last month and will run through the end of July in the Washington, D.C., region on the websites of prominent news outlets, in influential health care newsletters and on social media.</p><p>The AHA is joined in this effort by 340B Health, Children’s Hospital Association and the Catholic Health Association.</p><p><strong>AHA files briefs defending South Dakota and Tennessee 340B contract pharmacy laws</strong></p><p>The AHA last week filed an <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbCck5GsrBfd_K_8P-EoHGwSm8N_Ln8Dvq_4W1DzxSBGGpVXO5LStpztExOpGFEAUFsjO4Aq4%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cdac6a5161ef44e5d970108ddaab26bd1%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638854405500398442%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=l5fIWyLGABOz%2Fzug8BchD0SPgimfPhxYKSrTK3p2ki0%3D&reserved=0" target="_blank">amicus brief</a> in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies. The brief supports the state’s attempt to dismiss a case by AbbVie claiming that the state law is unconstitutional.</p><p>Joining the AHA in the Tennessee filing were 340B Health, the Tennessee Hospital Association and the American Society of Health-System Pharmacists.</p><p>The AHA May 14 filed a similar <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGbCck5GrHYeQhYa-WxwBkIAT6uhU8yK_WM-4A1a82tYvZ_Jf6vhYvtZQXNjNo3f1zRACPkBnk%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cdac6a5161ef44e5d970108ddaab26bd1%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638854405500410777%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=HFZJe00iW5Ns0EHhwdh5a6KWJ1hfRPlpw1hPbVF%2B7mI%3D&reserved=0" target="_blank">friend-of-the-court brief</a> in the U.S. District Court for the District of South Dakota. The brief supports the state’s attempt to dismiss a case by AbbVie claiming that the federal law that created the 340B program preempts the state law.</p><p>Joining the AHA in the South Dakota filing were 340B Health, the South Dakota Association of Healthcare Organizations and the American Society of Health-System Pharmacists. The AHA has filed briefs in similar cases for multiple states.</p> Fri, 13 Jun 2025 11:32:45 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-05-14-340b-advocacy-alliance-bulletin-may-14-2025 <p><strong>Use model letter to submit comments in advance of forthcoming 340B rebate proposal guidance; register for AHA 340B Alliance call May 15</strong></p><p>The AHA May 9 <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGabyossYQq26KcRJi2DNzqO4PwZMJHdG3IuRx9dYX6MZwsBxDGHstmesybTyS6R4ZiDrxatQM%3D&data=05%7C02%7Cdsamuels%40aha.org%7C26c6a3a280fb47c9b95f08dd931a859a%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638828464316427050%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=UqzBhzhrutxtBGcUxGlGKveNmMk4PkUmdS0kDBQe7%2FE%3D&reserved=0" target="_blank">urged</a> the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B Program is a vital lifeline for hospitals, particularly those serving rural and low-income communities,” AHA said. “If HHS authorizes these proposed ‘rebate models,’ it would come at the expense of America’s most vulnerable patients and communities.” HHS recently announced that it will be “in a position to provide guidance” about the drug industry’s proposed use of “rebate models” by the end of May.</p><p><strong>Model letter.</strong> The AHA has developed a model letter that hospitals and health systems can use to submit their own comments to HHS. <strong>The AHA strongly encourages all 340B hospitals to submit their own letters before HHS issues its expected guidance. </strong><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGabyossRWCCg7TQBIJ6xnPm93AKYiAuShPr_a1UGSqnqk_WC9vik2AxQDkAEOrv2M1DcrjZdE%3D&data=05%7C02%7Cdsamuels%40aha.org%7C26c6a3a280fb47c9b95f08dd931a859a%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638828464316439174%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=CwlQ6yRlH%2Be9663wtxgQxSM%2FGtwG9G%2Fk36zIM5YCfiw%3D&reserved=0" target="_blank"><strong>DOWNLOAD THE LETTER</strong></a><strong>.</strong> If you have any questions about the letter, please contact AHA General Counsel and Secretary Chad Golder at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGabyossdyva7QvyyzlbvzZzZj9OANIdZU0q3Y19pjhjcRgP25HqlXsxyIHmM-6-ROA_LXF7qk%3D&data=05%7C02%7Cdsamuels%40aha.org%7C26c6a3a280fb47c9b95f08dd931a859a%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638828464316450971%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=%2BM2wUJ50MgeH19heiSr2Wx3PxWhdvprP7sNDorPUij4%3D&reserved=0" target="_blank">cgolder@aha.org</a>.</p><p><strong>Register for May 15 call.</strong> As a reminder, the AHA 340B Advocacy Alliance will host a call May 15 at 3 p.m. ET to discuss how it plans to advocate against these proposed “rebate models” and how member hospitals can assist in this advocacy effort. <strong>This call is for AHA members only, and registration is required to participate. </strong><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGabyossdQj20eH2ZpkuBtTTKggq9DO1G1rZ6Md-sYEsKX0adsoWeYjCJZN1nfvXSbIbx2O9Wk%3D&data=05%7C02%7Cdsamuels%40aha.org%7C26c6a3a280fb47c9b95f08dd931a859a%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638828464316462803%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=E0GO%2FRSbFg1s%2FDUEQJV%2BJLXJdCGXpocZRlYMnABpY8E%3D&reserved=0" target="_blank"><strong>REGISTER NOW</strong></a><strong>.</strong> Registration will close at noon ET on May 15. If you have questions about registering, please contact Candice Dailey at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGabyossSwfFuoLTMjx2VodO20NB68p0Ko7mfapfnVyfhE6Y9imn6Azn8cC6xWjSa3GKqTy4WE%3D&data=05%7C02%7Cdsamuels%40aha.org%7C26c6a3a280fb47c9b95f08dd931a859a%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638828464316477515%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=0cOVWsf7cSGKVcm3Phd8WBQr5C8u6AqafYKUYQREXnA%3D&reserved=0" target="_blank">cdailey@aha.org</a>.</p> Wed, 14 May 2025 14:33:57 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-05-07-340b-advocacy-alliance-bulletin-may-7-2025 <p><strong>Register for May 15 AHA call to discuss upcoming HHS ‘rebate model’ guidance</strong></p><p>The AHA on Thursday, May 15 at 3 p.m. ET will host a call for member hospitals and health systems to discuss the Department of Health and Human Services’ recent announcement that it will be “in a position to provide guidance” about the drug industry’s proposed use of “rebate models” by the end of May. In particular, in a notice filed with the United States District Court for the District of Columbia, HHS stated:</p><p>"Large-scale implementation of rebate models to effectuate the 340B ceiling price would be a significant change for the 340B Program and its stakeholders. Because the implications are not straightforward, the Department of Health and Human Services continues to carefully evaluate its options alongside ongoing efforts to address 340B program integrity matters and keeping in mind the approaching effective date of certain Inflation Reduction Act requirements. The Department expects to be in a position to provide guidance for stakeholders in thirty days."</p><p>On the call, the AHA will discuss how it plans to advocate against these proposed “rebate models” and how member hospitals can assist in this advocacy effort.</p><p><strong>This call is AHA members only, and registration is required to participate. </strong><a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGaSzo6fe8Fv-WiMlith8yyZvlSrIXcMTQnFxXjCgJIZuy_76QkCdj8TPUY4OuQntfCD1HDOi0%3D&data=05%7C02%7Cdsamuels%40aha.org%7Ce324cf5480a34e2e3b2f08dd8d9eb995%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638822435062046933%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=iYY%2Few0gdRNz8mxEZVDs0uAQW5y9Ka2g1a7BuVlhh94%3D&reserved=0" target="_blank"><strong>REGISTER NOW</strong></a><strong>.</strong> Registration will close at 5 p.m. ET on May 14. If you have questions about registering, please contact Candice Dailey at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGaSzo6fUAbtdtjYQ3YLhwuO0HT-lEHeOzwS32rYsOGyiowF42wov6VC9ZlaVqtlMMYY-OUVJ8%3D&data=05%7C02%7Cdsamuels%40aha.org%7Ce324cf5480a34e2e3b2f08dd8d9eb995%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638822435062059767%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=HLJ7ju20n%2B3oUNzKSKgaDMxV2Cw6vBj8OawVFgJpoJ8%3D&reserved=0" target="_blank">cdailey@aha.org</a>.</p><p><strong>NEXT STEPS</strong></p><p>The AHA will submit a letter to HHS well in advance of its 30-day consideration period and provide 340B hospitals and health systems with a model letter. <strong>The AHA strongly encourages all member hospitals to submit their own comment letters.</strong></p><p>If you have further questions, please contact Chad Golder, general counsel, at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGaSzo6fQCs8DTNhTYlbnrFmtzFtcgFpfRAsd71yt0qwDbKZ0TF8IU-LYVXjhIypjcLuZPqdzU%3D&data=05%7C02%7Cdsamuels%40aha.org%7Ce324cf5480a34e2e3b2f08dd8d9eb995%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638822435062072718%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=VvvITNidnQy8n4i%2Bu2sl2bN1W4m%2Bb%2BrTV3CRcNQiUCs%3D&reserved=0" target="_blank">cgolder@aha.org</a>, or Aimee Kuhlman, vice president of advocacy and grassroots, at <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGaSzo6fclGsx9v3i02Urqg4kf3QKDqCzXqiw0Ct-J1l3UKabQqDc9mWckfdZDlLN11s8c7Aq4%3D&data=05%7C02%7Cdsamuels%40aha.org%7Ce324cf5480a34e2e3b2f08dd8d9eb995%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638822435062088979%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=cue01HuzPpm%2B%2BD3iucNMqPmqt2ZWnGcDrvZkUNQwBwE%3D&reserved=0" target="_blank">akuhlman@aha.org</a>.</p> Wed, 07 May 2025 14:43:19 -0500 340B Advocacy Alliance Bulletin /340b-advocacy-alliance-bulletin/2025-04-24-340b-advocacy-alliance-bulletin-april-24-2025 <p><strong>Cassidy releases report calling for reforms to 340B program</strong></p><p>Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGaCFismbHKeDhurue9tn-CxwS0pXoPRhuPCuCnZR-6siYu9ybDt0gNrquqtH4yvPy9K06PwL8%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cd4cddcf432dc4242c02008dd836a2d50%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638811214273726918%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=pBSNn5sZw20zEgWM%2BdeGxPIdSsORfNPVAKoDNCdeqWg%3D&reserved=0" target="_blank">report</a> detailing findings from an investigation into how covered entities use and generate revenue from the 340B Drug Pricing Program. As part of his investigation, Cassidy requested information from hospitals, Federally Qualified Health Centers, contract pharmacies and drug manufacturers.</p><p>Cassidy <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Femail.advocacy.aha.org%2FNzEwLVpMTC02NTEAAAGaCFismbHz0UQR_iq24XlEm9cM9J1SkgnblgBx7shiVd4ENFti06haCSXPg0ry4ccE3Q6pi6Y%3D&data=05%7C02%7Cdsamuels%40aha.org%7Cd4cddcf432dc4242c02008dd836a2d50%7Cb9119340beb74e5e84b23cc18f7b36a6%7C0%7C0%7C638811214273739178%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=abOupc5B9O9SEamJeBN9ktDp2v7LlIwklc21cqDzHmI%3D&reserved=0" target="_blank">said</a> the “investigation underscores that there are transparency and oversight concerns that prevent 340B discounts from translating to better access or lower costs for patients,” and the report outlines potential reforms needed to improve the program to better serve patients.</p><p>In a statement shared with media, AHA President and CEO Rick Pollack said, “The AHA appreciates Senator Cassidy’s leadership on 340B issues. As his report correctly observes, the 340B program was created to help hospitals reach more eligible patients and provide more comprehensive services. Even this investigation — which the report recognizes was ‘limited in scope’ given the variety of 340B hospitals across the country — demonstrates that hospitals use 340B savings to provide financial assistance to low-income patients and to maintain programs that enhance patient services and access to care. In short, 340B is vital in advancing health in communities across the country.</p><p>“We look forward to reviewing the report in greater detail, discussing it with our 340B members, and working with Senator Cassidy and others to ensure that the 340B program continues to benefit patients and communities, especially those in rural and other medically underserved areas.”</p> Thu, 24 Apr 2025 15:34:35 -0500 340B Advocacy Alliance Bulletin